The University of Southampton
University of Southampton Institutional Repository

Clinical impact of anti-inflammatory microglia and macrophage phenotypes at glioblastoma margins

Clinical impact of anti-inflammatory microglia and macrophage phenotypes at glioblastoma margins
Clinical impact of anti-inflammatory microglia and macrophage phenotypes at glioblastoma margins

Glioblastoma is a devastating brain cancer for which effective treatments are required. Tumour-associated microglia and macrophages promote glioblastoma growth in an immune-suppressed microenvironment. Most recurrences occur at the invasive margin of the surrounding brain, yet the relationships between microglia/macrophage phenotypes, T cells and programmed death-ligand 1 (an immune checkpoint) across human glioblastoma regions are understudied. In this study, we performed a quantitative immunohistochemical analysis of 15 markers of microglia/macrophage phenotypes (including anti-inflammatory markers triggering receptor expressed on myeloid cells 2 and CD163, and the low-affinity-activating receptor CD32a), T cells, natural killer cells and programmed death-ligand 1, in 59 human IDH1-wild-type glioblastoma multi-regional samples (n = 177; 1 sample at tumour core, 2 samples at the margins: the infiltrating zone and leading edge). Assessment was made for the prognostic value of markers; the results were validated in an independent cohort. Microglia/macrophage motility and activation (Iba1, CD68), programmed death-ligand 1 and CD4+ T cells were reduced, and homeostatic microglia (P2RY12) were increased in the invasive margins compared with the tumour core. There were significant positive correlations between microglia/macrophage markers CD68 (phagocytic)/triggering receptor expressed on myeloid cells 2 (anti-inflammatory) and CD8+ T cells in the invasive margins but not in the tumour core (P < 0.01). Programmed death-ligand 1 expression was associated with microglia/macrophage markers (including anti-inflammatory) CD68, CD163, CD32a and triggering receptor expressed on myeloid cells 2, only in the leading edge of glioblastomas (P < 0.01). Similarly, there was a positive correlation between programmed death-ligand 1 expression and CD8+ T-cell infiltration in the leading edge (P < 0.001). There was no relationship between CD64 (a receptor for autoreactive T-cell responses) and CD8+/CD4+ T cells, or between the microglia/macrophage antigen presentation marker HLA-DR and microglial motility (Iba1) in the tumour margins. Natural killer cell infiltration (CD335+) correlated with CD8+ T cells and with CD68/CD163/triggering receptor expressed on myeloid cells 2 anti-inflammatory microglia/macrophages at the leading edge. In an independent large glioblastoma cohort with transcriptomic data, positive correlations between anti-inflammatory microglia/macrophage markers (triggering receptor expressed on myeloid cells 2, CD163 and CD32a) and CD4+/CD8+/programmed death-ligand 1 RNA expression were validated (P < 0.001). Finally, multivariate analysis showed that high triggering receptor expressed on myeloid cells 2, programmed death-ligand 1 and CD32a expression at the leading edge were significantly associated with poorer overall patient survival (hazard ratio = 2.05, 3.42 and 2.11, respectively), independent of clinical variables. In conclusion, anti-inflammatory microglia/macrophages, CD8+ T cells and programmed death-ligand 1 are correlated in the invasive margins of glioblastoma, consistent with immune-suppressive interactions. High triggering receptor expressed on myeloid cells 2, programmed death-ligand 1 and CD32a expression at the human glioblastoma leading edge are predictors of poorer overall survival. Given substantial interest in targeting microglia/macrophages, together with immune checkpoint inhibitors in cancer, these data have major clinical implications.

Glioblastoma, biomarker, heterogenity, immunotherapy, intratumoural, macrophage, microglia, glioblastoma, intratumoural heterogeneity
2632-1297
fcad176
Noorani, Imran
d73f97c0-2dc7-4d7e-be31-e2d2f0b3131d
Sidlauskas, Kastytis
cff5dc27-513f-4bdb-af46-b1ccb5bfc991
Pellow, Sean
46d3aebb-b7f7-454b-a39e-fae24e573959
Savage, Reece
de601939-fc8b-4c0b-a2a7-65c148b2269f
Norman, Jeannette L.
56fb5b14-99a1-4902-994d-3f713cc6d76e
Chatelet, David S.
6371fd7a-e274-4738-9ccb-3dd4dab32928
Fabian, Mark
3f5c9bf4-e677-4ea9-ac69-2b61d8a96f52
Grundy, Paul
0ceddba7-59f8-469f-8b50-4d08936e92a0
Ching, Jeng
707101b5-8987-49c3-a690-25160d34d5cd
Nicoll, James A.R.
88c0685f-000e-4eb7-8f72-f36b4985e8ed
Boche, Delphine
bdcca10e-6302-4dd0-919f-67218f7e0d61
Noorani, Imran
d73f97c0-2dc7-4d7e-be31-e2d2f0b3131d
Sidlauskas, Kastytis
cff5dc27-513f-4bdb-af46-b1ccb5bfc991
Pellow, Sean
46d3aebb-b7f7-454b-a39e-fae24e573959
Savage, Reece
de601939-fc8b-4c0b-a2a7-65c148b2269f
Norman, Jeannette L.
56fb5b14-99a1-4902-994d-3f713cc6d76e
Chatelet, David S.
6371fd7a-e274-4738-9ccb-3dd4dab32928
Fabian, Mark
3f5c9bf4-e677-4ea9-ac69-2b61d8a96f52
Grundy, Paul
0ceddba7-59f8-469f-8b50-4d08936e92a0
Ching, Jeng
707101b5-8987-49c3-a690-25160d34d5cd
Nicoll, James A.R.
88c0685f-000e-4eb7-8f72-f36b4985e8ed
Boche, Delphine
bdcca10e-6302-4dd0-919f-67218f7e0d61

Noorani, Imran, Sidlauskas, Kastytis, Pellow, Sean, Savage, Reece, Norman, Jeannette L., Chatelet, David S., Fabian, Mark, Grundy, Paul, Ching, Jeng, Nicoll, James A.R. and Boche, Delphine (2023) Clinical impact of anti-inflammatory microglia and macrophage phenotypes at glioblastoma margins. Brain Communications, 5 (3), fcad176, [fcad176]. (doi:10.1093/braincomms/fcad176).

Record type: Article

Abstract

Glioblastoma is a devastating brain cancer for which effective treatments are required. Tumour-associated microglia and macrophages promote glioblastoma growth in an immune-suppressed microenvironment. Most recurrences occur at the invasive margin of the surrounding brain, yet the relationships between microglia/macrophage phenotypes, T cells and programmed death-ligand 1 (an immune checkpoint) across human glioblastoma regions are understudied. In this study, we performed a quantitative immunohistochemical analysis of 15 markers of microglia/macrophage phenotypes (including anti-inflammatory markers triggering receptor expressed on myeloid cells 2 and CD163, and the low-affinity-activating receptor CD32a), T cells, natural killer cells and programmed death-ligand 1, in 59 human IDH1-wild-type glioblastoma multi-regional samples (n = 177; 1 sample at tumour core, 2 samples at the margins: the infiltrating zone and leading edge). Assessment was made for the prognostic value of markers; the results were validated in an independent cohort. Microglia/macrophage motility and activation (Iba1, CD68), programmed death-ligand 1 and CD4+ T cells were reduced, and homeostatic microglia (P2RY12) were increased in the invasive margins compared with the tumour core. There were significant positive correlations between microglia/macrophage markers CD68 (phagocytic)/triggering receptor expressed on myeloid cells 2 (anti-inflammatory) and CD8+ T cells in the invasive margins but not in the tumour core (P < 0.01). Programmed death-ligand 1 expression was associated with microglia/macrophage markers (including anti-inflammatory) CD68, CD163, CD32a and triggering receptor expressed on myeloid cells 2, only in the leading edge of glioblastomas (P < 0.01). Similarly, there was a positive correlation between programmed death-ligand 1 expression and CD8+ T-cell infiltration in the leading edge (P < 0.001). There was no relationship between CD64 (a receptor for autoreactive T-cell responses) and CD8+/CD4+ T cells, or between the microglia/macrophage antigen presentation marker HLA-DR and microglial motility (Iba1) in the tumour margins. Natural killer cell infiltration (CD335+) correlated with CD8+ T cells and with CD68/CD163/triggering receptor expressed on myeloid cells 2 anti-inflammatory microglia/macrophages at the leading edge. In an independent large glioblastoma cohort with transcriptomic data, positive correlations between anti-inflammatory microglia/macrophage markers (triggering receptor expressed on myeloid cells 2, CD163 and CD32a) and CD4+/CD8+/programmed death-ligand 1 RNA expression were validated (P < 0.001). Finally, multivariate analysis showed that high triggering receptor expressed on myeloid cells 2, programmed death-ligand 1 and CD32a expression at the leading edge were significantly associated with poorer overall patient survival (hazard ratio = 2.05, 3.42 and 2.11, respectively), independent of clinical variables. In conclusion, anti-inflammatory microglia/macrophages, CD8+ T cells and programmed death-ligand 1 are correlated in the invasive margins of glioblastoma, consistent with immune-suppressive interactions. High triggering receptor expressed on myeloid cells 2, programmed death-ligand 1 and CD32a expression at the human glioblastoma leading edge are predictors of poorer overall survival. Given substantial interest in targeting microglia/macrophages, together with immune checkpoint inhibitors in cancer, these data have major clinical implications.

Text
fcad176 - Version of Record
Available under License Creative Commons Attribution.
Download (19MB)

More information

Accepted/In Press date: 1 June 2023
Published date: 2 June 2023
Additional Information: Funding Information: The study was supported by the British Neuropathological Society and the Pathological Society of Great Britain and Ireland. I.N. is funded by an National Institute of Health Research Clinical Lectureship, University College London Biomedical Research Centre, the Academy of Medical Sciences and The Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001169), the UK Medical Research Council (FC001169) and the Wellcome Trust (FC001169). Funding Information: Tissue samples were obtained from the University Hospital Southampton NHS Foundation Trust as part of BRAIN UK, which is supported by Brain Tumour Research, the British Neuropathological Society and the Medical Research Council. The authors acknowledge the Research Histology from the pathology department that retrieves the tissue, and the Histochemistry Research Unit and the Biomedical Imaging Unit facilities of the Faculty of Medicine that facilitated tissue processing, staining and analysis. Publisher Copyright: © The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain.
Keywords: Glioblastoma, biomarker, heterogenity, immunotherapy, intratumoural, macrophage, microglia, glioblastoma, intratumoural heterogeneity

Identifiers

Local EPrints ID: 477885
URI: http://eprints.soton.ac.uk/id/eprint/477885
ISSN: 2632-1297
PURE UUID: 0edbe4a9-e241-4960-a805-168abefd983e
ORCID for James A.R. Nicoll: ORCID iD orcid.org/0000-0002-9444-7246
ORCID for Delphine Boche: ORCID iD orcid.org/0000-0002-5884-130X

Catalogue record

Date deposited: 15 Jun 2023 17:04
Last modified: 17 Mar 2024 02:55

Export record

Altmetrics

Contributors

Author: Imran Noorani
Author: Kastytis Sidlauskas
Author: Sean Pellow
Author: Reece Savage
Author: Jeannette L. Norman
Author: David S. Chatelet
Author: Mark Fabian
Author: Paul Grundy
Author: Jeng Ching
Author: Delphine Boche ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×